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A Critical Appraisal of Implantable
Cardioverter-Defibrillator Therapy for
the Prevention of Sudden Cardiac Death
Roderick Tung, MD, Peter Zimetbaum, MD, Mark E. Josephson, MD
Boston, Massachusetts
The indications for implantable cardioverter-defibrillators (ICDs) for the prevention of sudden cardiac death have
rapidly expanded over the past 10 years. Clinical trial data have quickly been implemented into guidelines with-
out critical reassessment of the strengths and limitations of the evidence. ICD therapy has inherent risks includ-
ing infection, unnecessary shocks, potential for proarrhythmia, device malfunction, highly publicized manufac-
turer advisories, and procedural complications, which can adversely affect morbidity and quality of life. A
reappraisal of the benefits and potential hazards of ICD therapy will enable physicians to a have a more mutu-
ally informed and balanced dialogue with their patients. (J Am Coll Cardiol 2008;52:1111–21) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.058a
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tince the first descriptions of external defibrillation in the
960s and the first human implantable cardioverter-
efibrillator (ICD) in 1980 by Mirowski (1), the paradigm
or the prevention of sudden cardiac death shifted away
rom both antiarrhythmic drug and ablative strategies. After
he publication of the AVID (Antiarrhythmics Versus
mplantable Defibrillators) trial (2) for secondary preven-
ion, ICD therapy has been tested in broader and lower-risk
rimary prevention populations, transforming it from a
estricted “last resort” to a broad-reaching pre-emptive
herapy. In the past 15 years, the annual insertion of ICDs
as increased by 20-fold (3).
While the high stakes and unpredictable nature of sudden
ardiac death justifiably provoke fear and uncertainty, emo-
ional factors should not outweigh scientific evidence. ICD
herapy, priced up to $30,000 per device, has attendant
osts. The principle of nonmaleficence necessitates weigh-
ng any lifesaving benefit against the potential for harm, in
he form of unnecessary shocks, procedural complications,
nfection, device malfunction, manufacturer recalls, and
ossible proarrhythmia.
We offer a critical review of the ICD literature that
hallenges the appropriateness of current practice patterns
nd guidelines for ICD insertion on the grounds that: 1)
he clinical benefit has been overestimated by clinical
rials; 2) the adverse effects on morbidity, quality of life,
rom the Department of Medicine, Cardiovascular Division, Beth Israel Deaconess
edical Center, Boston, Massachusetts. Dr. Josephson has received educational
rants and honoraria from Medtronic.m
Manuscript received March 24, 2008; revised manuscript received May 19, 2008,
ccepted May 27, 2008.nd the potential for proarrhythmia have been underes-
imated; and 3) the unfavorable cost-effectiveness of ICD
herapy is understated.
ave We Overestimated the
linical Benefits of ICD Therapy?
tacking the deck: antiarrhythmic drugs as “control” arm
nd beta-blocker inequity. With the exception of the
CD-HeFT (Sudden Cardiac Death Heart Failure Trial)
4), CASH (Cardiac Arrest Study Hamburg) (5), and
USTT (Multicenter Unsustained Ventricular Tachycar-
ia Trial) studies (6), the patients in ICD trials randomized
o the “control” arm received antiarrhythmic drug therapy.
hile significant differences between randomized groups
ay be attributed to the superiority of the active treatment
ested, the possibility of an inferior performance in the
control” arm, worse than that of placebo, must not be
verlooked. Although there was a prevailing sentiment that
andomizing patients to placebo was unethical, not a single
andomized prospective trial has demonstrated improved
verall mortality from antiarrhythmic therapy. In fact,
everal signals that are of concern that suggest increased
ortality from antiarrhythmic therapy when compared with
lacebo have been seen in recent trials.
The potential for harm from antiarrhythmic therapy has
een historically well documented in trials like the CAST
Cardiac Arrhythmia Suppression Trial) and SWORD
Survival with Oral D-Sotalol Trial) studies (7,8). The
ropafenone active treatment arm had to be discontinued in
he CASH study due to a 61% increase in mortality at 11
onths (5).
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Reappraisal of Defibrillator Therapy September 30, 2008:1111–21In the MADIT I (Multicenter
Automatic Defibrillator Implan-
tation Trial) study (9), patients in
the control group had a 10%
higher mortality rate if they were
taking amiodarone at 1 month
(36% amiodarone vs. 26% no
amiodarone).
In 2 trials of ICD with “pla-
cebo” control groups, antiar-
rhythmic therapy performed
worse than standard therapy. In
the SCD-HeFT study, amioda-
rone was significantly worse than
placebo (hazard ratio [HR]:
1.44, 95% confidence interval
CI]: 1.05 to 1.97, p  0.01) in the pre-specified New York
eart Association (NYHA) functional class III patients.
owever, this trend was not seen in the overall study. In
he MUSTT trial, patients that were randomized to
lectrophysiologic-guided antiarrhythmic therapy had worse
utcomes than those who were randomized to no antiar-
hythmic therapy (Fig. 1). No formal comparison was
ommented upon, despite a 10% absolute increased inci-
ence of death at 5 years.
Beta-blocker utilization, which has been demonstrated to
educe arrhythmic and all-cause mortality in the post-
yocardial infarction and chronic systolic dysfunction set-
ings, can affect the outcome of ICD trials. First, higher
tilization of beta-blockade decreases overall event rates,
hich diminishes the power of a study to demonstrate
enefit from ICD therapy if the sample size is not increased.
urthermore, if patients randomized to ICD were dispro-
ortionately treated with higher rates of beta-blockade,
verall benefit seemingly from ICD would be accentuated.
his indeed was the case in 3 of the 4 trials that have proven
ignificant survival benefit with ICDs (Table 1).
rials in secondary prevention: reconsidering the AVID,
IDS (Canadian Implantable Defibrillator Study), and
ASH trials. The AVID trial (2) is the only trial to
emonstrate statistically significant mortality reduction
rom ICD therapy in secondary prevention. Randomizing
,016 patients with resuscitated ventricular fibrillation (VF),
ustained ventricular tachycardia (VT) with syncope, or
ymptoms with an ejection fraction (EF) 40% to either
CD or predominantly amiodarone-based antiarrhythmic
herapy, the study was prematurely discontinued due to a
% absolute increase in death in the antiarrhythmic group at
8 months (24.0% vs. 15.8%, p 0.02). Although statistical
djustments were attempted, it is difficult to overlook the
3-fold utilization of beta-blockers in the ICD group
38.1% vs. 11.0% at 1 year) and the 5% higher incidence of
trial fibrillation and NYHA functional class III heart
ailure in the antiarrhythmic group as additive confounding
Abbreviations
and Acronyms
CI  confidence interval
CRT  cardiac
resynchronization therapy
EF  ejection fraction
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
NYHA  New York Heart
Association
VF  ventricular fibrillation
VT  ventricular
tachycardiaariables that amplified net clinical benefit in favor of ICD therapy. Moreover, clinical benefit was not observed in
atients with an EF 35% and 20% (10).
While the number needed to treat in this trial was 11
CD implants to save 1 life, the unadjusted improvement in
ean survival was only 0.21 year, or 2.6 months (31 vs. 29
onths). This small difference was reduced by 15% when
djustments were made for heart failure and EF. This
odest prolongation of life was valued at $85,522 (11),
hich included the untoward costs of the 4% absolute
ncrease in rehospitalizations in the ICD group (60% vs.
6%, p  0.04).
Two smaller randomized trials, the CIDS (12) and
ASH (5) trials, failed to demonstrate statistically signifi-
ant reductions in mortality with ICD therapy for secondary
revention. These findings occurred despite similar inequi-
ies of beta-blockade therapy in ICD patients in the CIDS
Figure 1 Antiarrhythmic Therapy Can
Perform Worse Than Placebo
Inferior performance of antiarrhythmic therapy compared with control group in
the SCD-HeFT (Sudden Cardiac Death Heart Failure Trial) trial New York Heart
Association functional class III patients (top) and the MUSTT (Multicenter
Unsustained Ventricular Tachycardia Trial) trial (bottom). CI  confidence inter-
val; EPG  electrophysiology-guided; ICD  implantable
cardioverter-defibrillator.rial, with significantly higher event rates (44.4% in the
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September 30, 2008:1111–21 Reappraisal of Defibrillator TherapyASH trial, 29.6% in the CIDS trial, and 24.0% in the
VID trial in control arms) and longer follow-up (57
onths in the CASH trial, 36 months in the CIDS trial,
nd 18 months in the AVID trial). By current clinical trial
tandards, these trials, which did not meet conventional
tatistical significance, may not pass muster with the Food
nd Drug Administration.
These nonsignificant trends in favor of ICD therapy
rompted a meta-analysis that showed a significant differ-
nce in mortality in favor of ICD (13). With a combined
ollow-up period of 6 years, patients with defibrillators lived
nly 4.4 months longer than those treated with antiarrhyth-
ic therapy, and all statistically significant differences were
onsustained, narrowing at 4 years toward negligible after 6
ears. As seen in the AVID trial, patients with an EF35%
id not experience survival benefit from ICD therapy. In
ummary, the benefit of ICD for aborting death in selected
igh-risk patients is consistent but modest across these 3
rials.
rimary prevention in ischemic cardiomyopathy. The
requently quoted MADIT I study is ironically one of the
mallest ICD trials to date (n  196). Inclusion criteria
equired an EF of 35% and prior myocardial infarction
ith inducible sustained VT, which could not be suppressed
ith procainamide (9). Although ICD therapy did improve
urvival by 23% over conventional therapy (74% amiodarone
tilization) at 5 years, more of these deaths were spared
rom nonarrhythmic, noncardiac, and unknown causes (n 
4) than from arrhythmic death (n  10), when compared
ith that seen with conventional therapy. While misclassi-
cation is a possibility, this implausible improvement in
ortality may have been the result of a statistical aberration
ue to small sample size.
The results of the MADIT I study are not generalizable
o current medical practice for several reasons. While
eta-blockers (8% conventional vs. 26% ICD at discharge)
nd angiotensin-converting enzyme inhibitors (55% con-
entional vs. 60% ICD at discharge) were used more
requently in ICD patients at 1 month, the overall low rate
f medication administration is not in compliance with
isparate Rates of Beta Blockade in Major ICD Trials
Table 1 Disparate Rates of Beta Blockade in Major ICD Trials
Significant Mortality
Benefit Demonstrated
ICD
(%)
Control Group
(%)
AVID* (n  1,016) 42 16
MADIT I* (n  196) 26 8
MADIT II (n  1,232) 70 70
SCD-HeFT* (n  2,521) 82 79
Statistical significance between groups; †treatment differences may be confounded by higher us
AMIOVERT  Amiodarone versus Implantable Defibrillator in Patients with Nonischemic Cardiom
mplantable Defibrillators trial; CABG Patch Coronary Artery Bypass Graft Patch trial; CASH Car
EFINITE  Defibrillator in Non-Ischemic Cardiomyopathy Treatment Evaluation trial; DINAMIT 
ulticenter Automatic Defibrillator Implantation Trial; SCD-HeFT  Sudden Cardiac Death in Hearurrent post-myocardial infarction treatment guidelines. cata from patients that were screened and excluded were
ot available; therefore, the denominator for this highly
elected population remains unknown. Additionally, there
re no data on those patients who were suppressible with
rocainamide. Lastly, induction of sustained ventricular
rrhythmias and procainamide suppression is rarely per-
ormed in current practice, and this feature may have been
mportant for identifying patients more likely to experience
dverse events (mortality rate 39%).
The larger MADIT II study, enrolling 1,232 patients
ith coronary artery disease and an EF 30%, demon-
trated a 5.6% absolute mortality benefit (19.8% vs. 14.2%)
t 20 months in patients receiving ICDs (14). This differ-
nce, the smallest difference seen in any statistically signif-
cant ICD trial, was likely attenuated by the equivalent high
ate of beta-blockade (70%) and low rates of amiodarone
herapy in both groups (13% ICD vs. 10% control group).
n unexpected 5% absolute increase in hospitalizations for
ew or worsened congestive heart failure was seen in the
CD group (19.9% vs. 14.9%). Of note, only one-third of
he patients were followed for 2 years at the time the study
as stopped.
ide effects of device therapy: reprogramming the mode
f death. While acknowledging that the task of classifying
eath is fraught with problems, studies that attempt to
ifferentiate between modes of death provide interesting
nsights. The AVID and MADIT II studies did not
ttempt to classify the exact mechanism of death in the
riginal publications, and the MADIT I study suggested
hat ICD therapy not only prevented arrhythmic death, but
lso was a biologically implausible panacea for all causes of
eath. While an ICD cannot be expected to reduce nonar-
hythmic deaths, it should be expected to not increase the
ncidence of nonarrhythmic deaths as a side effect. This was
ot the case in both the CABG Patch (Coronary Artery
ypass Graft-Patch) and DINAMIT (Defibrillators in
cute Myocardial Infarction Trial) studies.
The CABG Patch trial randomized 900 patients with an
F 35% with abnormal signal-averaged electrocardio-
rams to the epicardial ICD or control group at the time of
Nonsignificant
Differences Shown
ICD
(%)
Control Group
(%)
CABG Patch (n  900) 19 16
CAT (n  104) 4 4
AMIOVIRT (n  103) 53 50
DEFINITE (n  450) 85 85
DINAMIT (n  674) 87 86
CIDS† (n  659) 37 21
CASH (n  288) 0 96
sotalol and class I drugs in ICD group.
hy and Asymptomatic Nonsustained Ventricular Tachycardia study; AVID  Antiarrythmics Versus
st Study Hamburg; CAT Cardiomyopathy Trial; CIDS Canadian Implantable Defibrillator Study;
llator in Acute Myocardial Infarction Trial; ICD  implantable cardioverter-defibrillator; MADIT 
e Trial.age of
yopat
dic Arreoronary artery bypass grafting (15). No demonstrable
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Reappraisal of Defibrillator Therapy September 30, 2008:1111–21ortality benefit was seen in patients receiving adjunctive
CD therapy, and many have attributed this finding to the
avorable effects of revascularization on arrhythmic sub-
trates. Although no randomized trials have evaluated the
ffects of revascularization on ventricular arrhythmias, ob-
ervational studies suggest that revascularization has no
ffect on sustained monomorphic VT or VF in association
ith prior infarction or depressed EF (16,17). The inci-
ence of arrhythmic death in the CABG Patch trial was
ndeed significantly reduced (29% control group vs. 15%
CD, p  0.024), but an unexpected increase in death from
ther causes in patients randomized to ICD therapy led to
n overall neutral effect (HR: 1.07, 95% CI: 0.81 to 1.42).
high incidence of death was seen in the first 30 days,
nd procedural device-related morbidity was seen with a
ignificantly higher incidence of sternal and wound in-
ections, which may have been due to the usage of
urgically implanted epicardial patches and longer oper-
tive times (18).
A similar phenomenon was seen in the more recently
ublished DINAMIT trial, which examined the role of
CDs in 674 patients 6 to 40 days status post-acute
yocardial infarction with an EF of 35% and impaired
utonomic tone (19). The prevention of arrhythmic death
ith ICDs (HR: 0.42, 95% CI: 0.22 to 0.83, p 0.009) was
ounterbalanced by excess death from nonarrhythmic etiol-
gies (HR: 1.75, 95% CI: 1.11 to 2.76, p  0.02). The
uthors speculated that successful abortion of sudden car-
iac death merely shifted the mode of death to pump failure.
he potential for causal harm from ICD shocks was
uggested by a substudy that showed the increased risk from
onarrhythmic death to be confined only to those that
eceived ICD discharges.
This signal of increased nonarrhythmic deaths in both
rials cannot be ignored as either an undesirable byproduct
f ICD therapy or merely a shift into a competing mode of
xit. In the case of heart failure, one could argue that death
rom pump dysfunction is substantially more morbid than
udden arrhythmic death.
iscordance between evidence and guidelines in the
ost-myocardial infarction setting. The 2006 recommen-
ations for primary prevention ICD in patients with post-
yocardial infarction left ventricular dysfunction aggregates
eterogeneous trial data into a final EF cutoff of40% (20).
hile one can recognize the difficulty of synthesizing trials
ith different inclusion criteria, not a single trial has utilized
n EF cutoff of 40% with the exception of the MUSTT
rial, which was not a defibrillator trial but rather a trial of
isk stratification using electrophysiologic study. This liberal
utoff may be a movement in the wrong direction, as the
verage EFs in these trials were substantially lower than the
nclusion cutoffs. The average EF for patients enrolled in
he AVID, MADIT I, MADIT II, SCD-HeFT, and
USTT studies was 27%. Accordingly, the recently up-
ated 2008 guidelines for device-based therapy abandoned
n all-encompassing EF cutoff in favor of trial-specific gnclusion criteria (21). As mentioned previously, the high-
isk selection of drug-refractory VT induced at electrophysi-
logic study in the MADIT I (39% mortality at 2 years) and
USTT (32% mortality at 5 years) studies is not incorpo-
ated in these guidelines.
The optimal timing of defibrillator insertion after myo-
ardial infarction remains unresolved. The findings of the
INAMIT study contradict the inferences from the VAL-
ANT (Valsartan in Acute Myocardial Infarction Trial)
tudy (22), which showed that patients with reduced systolic
unction were at the highest risk for sudden cardiac death in
he first 30 days after myocardial infarction. While guide-
ines have adopted a 40-day blanking period from the
INAMIT study, a gap in data exists from the imme-
iate to chronic setting, as the majority of patients in the
ADIT I and II studies were enrolled outside of 6 months
fter myocardial infarction (75% and 88%, respectively).
he mean interval from index myocardial infarction in the
ADIT II study was 6.7 years. A bimodal distribution of
isk was suggested by the time-dependent benefit of ICD in
he MADIT II study, which found benefit only for remote
vents outside of 18 months that persisted out to 15 years after
ndex myocardial infarction (23).
The upper boundary of risk with advanced age must be
empered by rationality, as patients over the age of 80 years
ere appropriately excluded from the MADIT I study.
hile they remain at highest risk for sudden cardiac death,
omprising over 65% of 465,000 out-of-hospital deaths in
999 (24), routine insertion in elderly patients who would
therwise qualify for ICD is philosophically debatable.
lthough there was no age cutoff in the SCD-HeFT and
ADIT II studies for enrollment, the median age of
atients in the SCD-HeFT study was 61 years, and mean
ge in the MADIT II study was 64  10 years.
onsignificance in nonischemics. Despite the inclusion
f the nonischemic etiologies into class I ICD primary
revention recommendations, not a single trial has demon-
trated a statistically significant mortality benefit from ICD
herapy in this group. The CAT (Cardiomyopathy Trial)
EF 30%, n  104) and the AMIOVIRT (Amiodarone
ersus Implantable Cardioverter Defibrillator Trial) studies
EF 35% with nonsustained VT, n  103) were both
erminated prematurely due to futility (25,26). The largest
nd only prospective trial of exclusively nonischemic pa-
ients was the DEFINITE (Defibrillators in Non-Ischemic
ardiomyopathy Treatment Evaluation) trial, which ran-
omized 458 patients with EF 36% and nonsustained VT
o standard medical therapy or single-chamber ICD (27).
he primary end point of all-cause mortality failed to reach
tatistical significance at 29 months (14.1% control group
s. 7.2%, p  0.08). The low event rates in this study may
e attributed to the low usage of amiodarone in the control
roup and high equitable rates of beta-blockers (85%) and
ngiotensin-converting enzyme inhibitors (95%) as back-
round therapy.
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September 30, 2008:1111–21 Reappraisal of Defibrillator TherapyThe SCD-HeFT study was the largest primary preven-
ion defibrillator trial to date (4). With a combination of
schemic (52%) and nonischemic (48%) etiologies, 2,521
atients with an EF 35% and class II to III heart failure
ere randomized to conventional medical therapy, amioda-
one, or ICD therapy. Compared with placebo, ICD ther-
py reduced all-cause mortality from 29% to 22% at 45
onths (p  0.007). Pre-specified subgroup analysis was
erformed by NYHA functional class and etiology, and due
o 6 interim analyses of the data, the level of significance was
more stringent p value of 0.023. Neither ischemic nor
onischemic subgroups met statistical significance (p 0.05
nd 0.06, respectively). Interestingly, benefit from ICD was
een only in NYHA functional class II patients (HR: 0.54,
5% CI: 0.4 to 0.74, p  0.001), and amiodarone was
armful when compared with placebo in patients with
YHA functional class III (HR: 1.44, 95% CI: 1.05 to
.97, p  0.01). In accordance with statistical dictum,
ubgroup analysis should be hypothesis-generating, rather
han guideline-concluding. The nonsignificant benefit in
onischemic cardiomyopathy subgroup analysis was imple-
ented into guidelines, and lack of benefit in NYHA
Figure 2 Inappropriate Detection of Bigeminy With Proarrhythm
ICD  implantable cardioverter-defibrillator.unctional class III patients was left out. The inconclusive
ature of the data mentioned in the preceding text calls the
lass I, level B estimate of certainty into question for this
opulation.
ave We Underestimated the Risks of ICD?
CD shocks: “appropriate” does not equal necessary. In
perfect world, ICD therapy would treat only the events
hat were imminently and inevitably fatal. However, clinical
rial experience has revealed that up to 25% of patients
eceive inappropriate ICD shocks (28). These shocks are
ommonly due to double counting, oversensing, ectopy, and
upraventricular tachycardias, ranging from sinus tachycar-
ia to atrial fibrillation (Fig. 2). ICD shocks have consis-
ently been demonstrated to reduce overall quality of life and
ncrease the incidence of depression and anxiety while
bligating strict driving restrictions. Aside from morbidity,
hese shocks may have attendant lethal risks, as patients
eceiving inappropriate shocks in the SCD-HeFT study
ere at higher risk for death (HR: 1.97, 95% CI: 1.29 to
.01) (29).
om Antitachycardia Pacing Requiring ICD Shockia Fr
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Reappraisal of Defibrillator Therapy September 30, 2008:1111–21An examination of randomized trials for primary and
econdary prevention has shown that the number of appro-
riate shocks consistently exceeds the sudden death and
verall mortality rate in the control group (28) (Fig. 3).
adish et al. (27) reported twice as many events in the ICD
rm of the DEFINITE trial when compared with the
ontrol arm (32 shocks/1 death, ICD vs. 15 arrhythmic
eaths, control arm) (30). Two plausible explanations have
een proposed to explain this phenomenon. First, ICD
herapies may not be a surrogate for sudden cardiac
eath, as many episodes may have been nonsustained
onfatal events. This suggests that a distinction needs to
e made between shocks that are appropriate and shocks
hat are necessary. Alternatively, insertion of the device
ay be directly or indirectly proarrhythmic. There are
umerous speculated mechanisms by which an ICD may
romote arrhythmogenesis including device malfunction,
nduction of arrhythmias from inappropriate shocks,
acemaker-facilitated triggers, and reversal of activation
avefronts from epicardial resynchronization increasing
ispersion of refractoriness (31–35). Additionally, local
ead effects with mechanical irritation and late fibrosis
ay be a potential mechanism for VT (Fig. 4).
acing hazards. Recently, Sweeney et al. (36) analyzed the
ntracardiac initiation sequence of 1,356 VT/VF episodes
rom the PainFree Rx II and EnTrust trials and found
acing-associated short-long-short sequences at the onset of
Figure 3 Appropriate Shocks Outnumber Control Arrhythmic Mo
AMIOVIRT  Amiodarone Versus Implantable Cardioverter Defibrillator Trial; AVID
in Non-Ischemic Cardiomyopathy Treatment Evaluation trial; DINAMIT  Defibril
tor; MADIT II  Multicenter Automatic Defibrillator Implantation Trial II; MUSTT
diac Death Heart Failure Trial. Adapted from Germano et al. (28).1% to 35% of all episodes. They also found sudden-onset
nitiations that occurred during pacing in 29.8% of the
pisodes analyzed. The short-long-short sequences were
urther broken down into pacing-permitted and pacing-
acilitated onsets with a higher rate of the former in
anaged ventricular pacing and VVI modes when com-
ared with those in DDD. This study suggests that normal
acing system operation might constitute an important
echanism of device proarrhythmia. A smaller double
rossover study demonstrated that the cessation of backup
acing in patients with previous pacing-facilitated VT-VF
liminated VT-VF recurrences when compared with those
hat had backup pacing increased to a lower rate of 60
eats/min (37).
The precipitation of ventricular arrhythmias immediately
fter cardiac resynchronization therapy (CRT) has been
eported. Extreme examples of VT storm that are only
lleviated immediately after the discontinuation of left
entricular pacing have been seen (38). Cardiac resychroni-
ation with epicardial coronary sinus lead implantation
everses the typical transmural activation sequence, delaying
ndocardial depolarization and repolarization. Dispersion of
efractoriness and heterogeneity in conduction patterns has
een demonstrated to be arrhythmogenic in animal models
39). In the recent CARE-HF (Cardiac Resynchronization
eart Failure) trial, which demonstrated improvement in
ll-cause mortality from resynchronization, there was a
ty in 6 of 7 Trials
tiarrhythmics versus Implantable Defibrillators trial; DEFINITE  Defibrillators
in Acute Myocardial Infarction Trial; ICD  implantable cardioverter-defibrilla-
lticenter Unsustained Ventricular Tachycardia Trial; SCD-HeFT  Sudden Car-rtali
 An
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September 30, 2008:1111–21 Reappraisal of Defibrillator Therapyigher incidence in sudden death in patients receiving CRT
35.4% vs. 31.7%) (40). A similar signal was seen in the
OMPANION (Companion of Medical Therapy, Pacing
nd Defibrillation in Heart Failure) trial, with a 2% higher
ncidence of sudden death (7.8% vs. 5.8%) in the CRT arm
hen compared with that in the control arm (41). This may
e the reverse phenomenon of shifting modes of death as
een in the DINAMIT study. A recent meta-analysis of 14
rials, however, did not suggest any excess risk of sudden
eath from CRT (risk ratio: 1.07; 95% CI: 0.79 to 1.46)
espite a prior contrary suggestion seen on an analysis
erformed 3 years earlier by the same authors (HR: 1.99,
5% CI: 0.95 to 4.16). An additional meta-analysis dem-
nstrated a neutral effect despite a slightly higher rate of
udden cardiac death in the CRT arm (6.4% vs. 5.9%)
42,43).
ardware malfunction. Despite advances in ICD system
esign and manufacturing, devices remain imperfect. Struc-
ural failure of an implanted device has tremendous adverse
ffects on patient morbidity, both medically and psycholog-
cally. Inappropriate sensing due to conductor or insulation
racture, sensing lead adapter failure, loose set screws, or
rank dislodgement can lead to oversensing of electrical
oise with resultant inappropriate shocks. Kleemann et al.
44) reported on the suboptimal reliability of over 20 lead
odels over a 13-year period. Overall, 148 (15%) of 990
CD leads failed during follow-up, with estimated survival
ates of 85% and 60% at 5 and 8 years after implantation,
espectively.
In 2001, Maisel et al. (45) reported a recall rate of 16.4
er 100 person-years, with 54% for hardware malfunctions
nd 41% for programming malfunctions. In 2005, all 3 of
Figure 4 Proarrhythmia From Local Lead Effects?
Patient A presented with slow ventricular tachycardia initially, and rapid ventricular
ventricular catheter directly adjacent to the implantable cardioverter-defibrillator lea
able cardioverter-defibrillator shocks, and the closest pace map was from the right
apex.he major ICD manufacturing companies (St. Jude Photon/ qtlas, Guidant Ventak Prizm/Contak Renewal, Medtronic
arquis) issued advisories on the potential for ICD mal-
unction. Not unexpected, the public scrutiny of defibrillator
ecalls from 2005 brought the rampant insertion rate of
CDs to a screeching halt. Yet in the aftermath of this, the
ighly publicized recall of the Sprint Fidelis (Medtronic
nc., Minneapolis, Minnesota) lead was issued last October.
he higher rates of lead fracture (2.3% to 6.7% at 30
onths) led to more media-provoked mass hysteria as about
68,000 patients worldwide were at risk (46,47). Patients
xperiencing a lead complication are at risk for inappropri-
te shocks and ICD storm due to sensing of electrical noise
48) (Fig. 5). Five deaths linked to lead fracture-induced
roarrhythmia were reported in the initial advisory.
While the impact of recalls on patients is multiple and
vert, the burden upon physicians must not be overlooked as
here is little guidance on how to manage the “at-risk”
opulation. Routine explantation is seldom advised, and
ndividual cases are left up to the physician’s discretion by
he device companies. Several experienced centers reported
high rate of major complications (1.2% to 7.3%) from
eplacement of devices under advisory, ranging from reop-
ration to pocket infections, hematomas, and even death
49–52). From these data, the morbidity and mortality of
eplacing a device must not be underestimated.
ave We Overestimated the
ost-Effectiveness of ICD Therapy?
anders et al. (53) estimated the cost-effectiveness of ICD
herapy for primary prevention based on 8 randomized
ontrolled trials. At a cost between $34,000 to $70,200 per
cardia induced in the laboratory was successfully pace terminated from the right
paced morphology identical to tachycardia. Patient B presented with 28 implant-
icular catheter adjacent to the implantable cardioverter-defibrillator lead in thetachy
d with
ventruality-adjusted life year, the authors performed a sensitivity
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100,000 assuming that the benefit of ICD persisted after 7
ears. The projected life extension was 1.0 to 2.99 quality-
djusted life years based on the 6 trials showing benefit.
his Markov model assumed an ICD efficacy based on only
he 6 trials that demonstrated benefit and assumed a
enerator replacement every 5 years. The specific assump-
ions to account for hospitalizations, recurrent shocks, and
ead replacement were not elaborated.
An analysis of the SCD-HeFT study found significant
nteraction between NYHA functional class and ICD ther-
py and no incremental benefit despite higher costs in
atients with NYHA functional class III heart failure.
urthermore, incremental cost-effectiveness ratio was under
100,000 only after a sensitivity analysis extrapolated the
ime 3 years beyond the trial follow-up ($127,503 per
ife-year saved at 5 years, $88,657 per life-year saved at 8
ears) (54). In the United Kingdom, a comprehensive
eview by Buxton et al. (55) concluded that the utilization
cheme was not cost-effective, with a mean-discounted ICD
ost of €70,900 over a 20-year horizon for a mean gain of
.24 years. Assuming a persistent treatment effect, the cost
er life year was estimated at €32,000 (55).
The multivariable calculus of cost-effectiveness analysis is
eavily dependent on start-up cost estimates, projected
ollow-up care, and a fundamental assumption of persistent
Figure 5 Lethal Proarrhythmia
Inappropriate shocks for electrical noise in a primary prevention implantable
cardioverter-defibrillator recipient with a Sprint Fidelis lead. The sixth and final shoreatment effect. Reynolds et al. (56) reported a 10.8% early womplication rate in Medicare patients undergoing ICD
nsertion, associated with a mean cost of $42,184 and mean
tay of 4.7 days. The assumption that ICD therapy has a
ersistent effect on late survival has not been supported by
ata. In a meta-analysis of secondary prevention trials,
onvergence of the survival curves for ICD and control arms
as seen at 4 years (14). Furthermore, patients that receive
ppropriate ICD shocks appear to have a declining prog-
osis. Eleven percent of patients in the SCD-HeFT trial
ho received a single shock died within 24 h, and the
verage life expectancy thereafter was 1 year (29). In the
ADIT II study, the mortality rate of patients receiving
herapy for VF was over 50% at 2 years (57).
Based on the previously mentioned overestimation of
CD efficacy and the underestimation of “real-world” com-
lication rates, which leads to increased costs, the published
ime-extrapolated cost-effectiveness analyses are hypotheti-
al “best-case scenario” estimates. A cost-effectiveness anal-
sis based on the actual MADIT II study population within
he study time frame supports this assertion. ICD therapy
as associated with a 3-fold higher rate of hospitalizations,
nd the average survival gain was 2 months. Because of this
odest benefit, the incremental cost-effectiveness ratio was
n astounding $235,000 per year of life saved, unadjusted
or quality of life. The cost-effectiveness approached the
ccepted range of $50,000 to $100,000 only when the data
ced ventricular fibrillation (VF). EGM  electrogram.ck induere extrapolated to 12 years (58). A similar unfavorable
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revention, with life extension of 2.8 months priced at
213,543 per unadjusted year of life saved (59).
While many analyses attempt to adjust cost-effectiveness
or quality of life, there are many intangible impacts on
sychological well-being that cannot be made mathemati-
ally. While many patients are comforted by having a “safety
et,” ICD-specific fears including fear of death, shock, and
ublic embarrassment are commonly experienced by recip-
ents. In one study, symptoms of anxiety and depression
ersisted in 40% to 63% of defibrillator recipients at 1 year
60). Psychiatric studies have found that the aversive clas-
ical conditioning and dysfunctional cognition that occurs in
efibrillator shock recipients makes them a prototypical
odel for anxiety development (61,62). The adverse psy-
hological effects of increasing shock frequency has been
learly demonstrated in the quality-of-life analysis from the
VID, CIDS, and DEFINITE trials (63–65).
As current guidelines are being broadened to include
ower-risk groups with lower event rates, the cost-
ffectiveness will become even less favorable. In the case of
rimary prevention in nonischemic patients, a 20% appro-
riate shock rate approximates a 10% necessary life-saving
herapy rate. Therefore, 90% of patients that do not expe-
ience life-saving shocks are still exposed to the costs and
isks of device-related complications. A distinction between
herapeutic efficacy and efficiency needs to be recognized.
onclusions
CD therapy has clearly been shown to be effective in
borting sudden arrhythmic death. However, the extent to
ow much this capability, which modestly prolongs life,
utweighs potential adverse effects on morbidity, quality of
ife, and the mode of death is less clear. ICD insertion is
nlike an “insurance policy,” as patients who do not benefit
rom device therapy are still exposed to procedural and device-
elated complications. The intent of clinical trials and future
esearch should help physicians refine their selection of patients
ho are most likely to derive benefit and avoid harm from ICD
herapy. However, some of the current guidelines appear to
ave been implemented based on trials with nonsignificant p
alues and outdated practice standards. The obligation to
dhere to guidelines appears to have paradoxically dulled our
iscriminatory senses as clinicians.
With modern medicine, less emphasis has been placed on
he physician-patient dialogue where concerns and expec-
ations are freely exchanged. Physicians should understand
hat choosing longevity with potential tradeoffs in device-
elated complications and quality of life is a personal
ecision that must be individually tailored to patient pref-
rence. The process of obtaining informed consent from
atients mandates and pre-supposes that physicians, first,
re fully informed of the risks and benefits of the therapy
hat they are offering. It is ethically imperative that we are
1onest with the data, so that we can be honest with our
atients.
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